Abstract:Background Wiskott-Aldrich syndrome protein family member 2 (WASF2) has been shown to play an important role in many types of cancer. Therefore, it is worthwhile to further study expression profile of WASF2 in human cancer, which provides new molecular clues about the pathogenesis of ovarian cancer. Methods We used a series of bioinformatics methods to comprehensively analyze the relationship between WASF2 and prognosis, tumor microenvironment (TME), immune infiltration, tumor mutational burden (TMB), microsatellite instability (MSI), and tried to find the potential biological processes of WASF2 in ovarian cancer. Biological behaviors of ovarian cancer cells were investigated through CCK8 assay, scratch test and transwell assay. We also compared WASF2 expression between epithelial ovarian cancer tissues and normal ovarian tissues by using immunohistochemical staining. Results In the present study, we found that WASF2 was abnormally expressed across the diverse cancer and significantly correlated with overall survival (OS) and progression-free interval (PFI). More importantly, the WASF2 expression level also significantly related to the TME. Our results also showed that the expression of WASF2 was closely related to immune infiltration and immune-related genes. In addition, WASF2 expression was associated with TMB, MSI, and antitumor drugs sensitivity across various cancer types. Functional bioinformatics analysis demonstrated that the WASF2 might be involved in several signaling pathways and biological processes of ovarian cancer. A risk factor model was found to be predictive for OS in ovarian cancer based on the expression of WASF2. Moreover, in vitro experiments, it was demonstrated that the proliferative, migratory and invasive capacity of ovarian cancer cells was significantly inhibited due to WASF2 knockdown. Finally, the immunohistochemistry data confirmed that WASF2 were highly expressed in ovarian cancer. Conclusions Our study demonstrated that WASF2 expression was associated with a poor prognosis and may be involved in the development of ovarian cancer, which might be explored as a potential prognostic marker and new targeted treatments.

CST2 promotes cell proliferation and regulates cell cycle by activating Wnt-β-catenin signalling pathway in serous ovarian cancer

Gene expression analyses identify a relationship between stanniocalcin 2 and the malignant behavior of colorectal cancer.

Cystatin 2 leads to a worse prognosis in patients with gastric cancer

Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway

Reduced Expression of Sirt2 in Serous Ovarian Carcinoma Promotes Cell Proliferation Through Disinhibition of Cdk4 Expression

SCC-S2 is overexpressed in colon cancers and regulates cell proliferation

Cystatin SA attenuates gastric cancer cells growth and increases sensitivity to oxaliplatin via PI3K/AKT signaling pathway

Upregulation of SGOL2 Predicts Poor Prognosis and Facilitates Hepatocellular Carcinoma Progression via Dysregulating the Cell Cycle by Directly Activating MAD2

CCT2 prevented β-catenin proteasomal degradation to sustain cancer stem cell traits and promote tumor progression in epithelial ovarian cancer

Decreased CSTA Expression Promotes Lymphatic Metastasis and Predicts Poor Survival in Oral Squamous Cell Carcinoma.

Comprehensive analysis of suppressor of cytokine signaling 2 protein in the malignant transformation of NSCLC

SOX2 Enhances the Migration and Invasion of Ovarian Cancer Cells Via Src Kinase.

SPTLC2 drives an EGFR-FAK-HBEGF signaling axis to promote ovarian cancer progression

WASF2 Serves as a Potential Biomarker and Therapeutic Target in Ovarian Cancer: A Pan-Cancer Analysis

CpG-binding Protein CFP1 Promotes Ovarian Cancer Cell Proliferation by Regulating BST2 Transcription

High Expression of TBC1 Domain Family Member 22A is Related to Poor Prognosis in Ovarian Serous Cystadenocarcinoma

Ceramide Synthase 6 Predicts Poor Prognosis And Activates The Akt/Mtor/4ebp1 Pathway In High-Grade Serous Ovarian Cancer

CPT2 down-regulation promotes tumor growth and metastasis through inducing ROS/NFκB pathway in ovarian cancer

CTSG Suppresses Colorectal Cancer Progression Through Negative Regulation of Akt/mTOR/Bcl2 Signaling Pathway.

The role of CSTF2 in cancer: from technology to clinical application

Germ cell-specific gene 2 accelerates cell cycle in epithelial ovarian cancer by inhibiting GSK3α-p27 cascade